Connor, Clark & Lunn Investment Management (CC&L)’s Genomic Health, Inc. GHDX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,150	Closed	-$396K	–	1097
2018 Q4	$396K	Buy	+6,150	New	+$431K	﹤0.01%	750
2016 Q3	–	Sell	-12,195	Closed	-$316K	–	949
2016 Q2	$316K	Sell	12,195 -26,905	-69%	-$715K	﹤0.01%	664
2016 Q1	$969K	Sell	39,100 -21,000	-35%	-$576K	0.01%	465
2015 Q4	$2.12M	Buy	60,100 +13,600	+29%	+$364K	0.02%	332
2015 Q3	$984K	Buy	+46,500	New	+$1.2M	0.01%	404

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GHDX Position: Q1 2019 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Genomic Health, Inc. (GHDX) in Q1 2019, closing a stake of 6,150 shares — an estimated $396K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GHDX in Q3 2015 and held it in 5 quarters. The position peaked at $2.12M in Q4 2015. 267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Genomic Health, Inc. position as of Q1 2019 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 6,150 Genomic Health, Inc. shares in Q1 2019, an estimated $396K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Genomic Health, Inc. in Q3 2015 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Genomic Health, Inc. position peaked at $2.12M in Q4 2015.
267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2019, filed 8 May 2019.